Matches in Wikidata for { <http://www.wikidata.org/entity/Q87931861> ?p ?o ?g. }
Showing items 1 to 41 of
41
with 100 items per page.
- Q87931861 description "clinical trial" @default.
- Q87931861 description "ensayu clínicu" @default.
- Q87931861 description "klinisch onderzoek" @default.
- Q87931861 description "клінічне випробування" @default.
- Q87931861 name "Dabrafenib, Trametinib, and Spartalizumab for the Treatment of BRAF V600E or V600K Mutation Positive Stage IIIB/C/D Melanoma" @default.
- Q87931861 name "Dabrafenib, Trametinib, and Spartalizumab for the Treatment of BRAF V600E or V600K Mutation Positive Stage IIIB/C/D Melanoma" @default.
- Q87931861 type Item @default.
- Q87931861 label "Dabrafenib, Trametinib, and Spartalizumab for the Treatment of BRAF V600E or V600K Mutation Positive Stage IIIB/C/D Melanoma" @default.
- Q87931861 label "Dabrafenib, Trametinib, and Spartalizumab for the Treatment of BRAF V600E or V600K Mutation Positive Stage IIIB/C/D Melanoma" @default.
- Q87931861 prefLabel "Dabrafenib, Trametinib, and Spartalizumab for the Treatment of BRAF V600E or V600K Mutation Positive Stage IIIB/C/D Melanoma" @default.
- Q87931861 prefLabel "Dabrafenib, Trametinib, and Spartalizumab for the Treatment of BRAF V600E or V600K Mutation Positive Stage IIIB/C/D Melanoma" @default.
- Q87931861 P1050 Q87931861-973882C7-9962-4EAD-BDB7-37A0853B0B5B @default.
- Q87931861 P1132 Q87931861-B65DE108-1FAC-4A22-B961-7F91D0297489 @default.
- Q87931861 P1476 Q87931861-A90CF90C-9874-4FF2-9BEA-C063C8F38826 @default.
- Q87931861 P17 Q87931861-335A2944-B318-44C0-828E-713FDB9B216C @default.
- Q87931861 P2899 Q87931861-CD7C289C-31F7-4E43-A2A2-CFE75C162641 @default.
- Q87931861 P3098 Q87931861-E7C84437-6CB7-4FDA-ACFA-2A81A409CB29 @default.
- Q87931861 P31 Q87931861-E10A7C66-4370-4616-8B6A-8BF766F9D77F @default.
- Q87931861 P4844 Q87931861-99E7D514-0A50-4EE2-93E8-076B0D311ECD @default.
- Q87931861 P4844 Q87931861-EE39A011-AF2A-47E1-B5A1-E04A9B8AE979 @default.
- Q87931861 P580 Q87931861-CC100513-AFC6-47C9-8840-2255575583A5 @default.
- Q87931861 P582 Q87931861-45EDE0E8-4D91-441C-848C-66941E585743 @default.
- Q87931861 P6099 Q87931861-5F1021B7-ABDA-4C5F-87EE-7F68255DD103 @default.
- Q87931861 P767 Q87931861-C1BE7BBB-517C-47AC-8CFC-FEC583A1734B @default.
- Q87931861 P8363 Q87931861-6C8823C3-2812-480A-8D08-0E4992FFABCA @default.
- Q87931861 P859 Q87931861-F2A15AE6-0D97-4293-8DC2-E2C43B9B9DDD @default.
- Q87931861 P1050 Q180614 @default.
- Q87931861 P1132 "+45" @default.
- Q87931861 P1476 "Altering Adjuvant Therapy Based on Pathologic Response to Neoadjuvant Dabrafenib and Trametinib (ALTER-PATH NeoDT)" @default.
- Q87931861 P17 Q30 @default.
- Q87931861 P2899 "+18" @default.
- Q87931861 P3098 "NCT04310397" @default.
- Q87931861 P31 Q30612 @default.
- Q87931861 P4844 Q3011604 @default.
- Q87931861 P4844 Q7833138 @default.
- Q87931861 P580 "2020-01-29T00:00:00Z" @default.
- Q87931861 P582 "2022-02-28T00:00:00Z" @default.
- Q87931861 P6099 Q42824440 @default.
- Q87931861 P767 Q664846 @default.
- Q87931861 P8363 Q78089383 @default.
- Q87931861 P859 Q1525831 @default.